MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2019 International Congress

September 22-26, 2019. Nice, France.

View by Title View Sessions
View by Date

Monday, September 23, 2019

1:45pm-3:15pm
A phase IIa trial studying the safety and tolerability of IRL752 in patients with Parkinson’s disease dementia

P. Svenningsson, P. Odin, N. Dizdar, F. Bergquist, A. Johansson, D. Nyholm, K. Wictorin, J. Tedroff (Uppsala, Sweden)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3
1:45pm-3:15pm
A pilot study of the feasibility and effects of table tennis training in Parkinson’s Disease

K. Olsson, A. Johansson, E. Franzén (Stockholm, Sweden)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3
1:45pm-3:15pm
A Protocol to Test the Effects of TDCS on Consolidation of Writing Practice in Parkinson’s Disease

S. Broeder, T. Kramer, R. Meesen, G. Verheyden, JJ. Orban Dexivry, A. Nieuwboer (Leuven, Belgium)

Physical and Occupational Therapy  ·  Les Muses Terrace, Level 3
1:45pm-3:15pm
A randomized clinical trial of multimodal balance training with rhythmical cues: effects on freezing of gait in Parkinson’s disease

T. Capato, N. de Vries, J. Inthout, J. Ramjith, E. Barbosa, J. Nonnekes, B. Bloem (Nijmegen, Netherlands)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3
1:45pm-3:15pm
A randomized, placebo-controlled, double-blind clinical study in Japan of Opicapone treatment for Parkinson’s Disease -Comfort-PD Study part 1

A. Takeda, R. Takahashi, Y. Tsuboi, M. Nomoto, T. Maeda, A. Nishimura, N. Hattori (Sendai, Japan)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3
1:45pm-3:15pm
A recessive repeat expansion causes CANVAS and is a common cause of Late-Onset Ataxia

H. Houlden, M. Reilly, S. Zuchner, W. Marques, P. Fratta, A. Bronstein, A. Rossor, A. Rebelo, E. Buglo, N. Andrade, N. Wood, D. Kaski, S. Efthymiou, V. Salpietro, M. Versino, I. Callegari, D. Devigili, P. Tomaselli, E. Tribollet, M. Ilyas, J. Polke, P. Sivakumar, Z. Jaunmuktane, J. Humphrey, Y. Yan, H. Tariq, J. Vandrovcova, R. Sullivan, R. Simone, A. Cortese (London, United Kingdom)

Ataxia  ·  Les Muses, Level 3
1:45pm-3:15pm
A retrospective analysis of clinical and electrophysiological characteristics of patients with myoclonus

A. Gunduz, M. E. Kızıltan, H. Ser, N. Yeni, C. Ozkara, V. Demirbilek, C. Yalçınkaya, G. Kızıltan (Istanbul, Turkey)

Myoclonus  ·  Les Muses, Level 3
1:45pm-3:15pm
A review of interactive voice response systems in Parkinson’s Disease

J. Domingues, T. Guerreiro, D. Branco, A. Rodrigues, R. Bouça-Machado, J. Ferreira (Aveiro, Portugal)

Other  ·  Agora 2 West, Level 2
1:45pm-3:15pm
A Robust and Rapid Method of PCR amplification To Confirm Triplet Repeat Disorders: Single-Step Blood Direct PCR

I. Singh, V. Swarup, S. Shakya, V. Goyal, A. Srivastava (New Delhi, India)

Ataxia  ·  Les Muses, Level 3
1:45pm-3:15pm
A safety, tolerability and biomarker update from an ongoing open-label extension study of RG6042 in adults with early manifest Huntington’s disease

S. Tabrizi, B. Leavitt, P. Sanwald Ducray, E. Wild, V. Schlegel, G. Hooper, A. Nicotra, J. Chevure, A. Smith, R. Lane, F. Bennett, L. Boak, R. Doody, S. Schobel (London, United Kingdom)

Huntington’s Disease  ·  Agora 3 West, Level 3
  • «Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 75
  • Next Page»

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #25179 (not found)
  • Screening and Treatment of Depression in Parkinson’s Disease within Movement Disorders Centers: A Quality Improvement Initiative
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • DaTscan in clinical evaluation of Multiple System Atrophy
  • Decision-making process for opicapone’s bedtime regimen
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley